Αρχική World News Oncogenic Drivers Associated with Late Recurrence in Postmenopausal Women with ER-positive/HER2-negative Early...

Oncogenic Drivers Associated with Late Recurrence in Postmenopausal Women with ER-positive/HER2-negative Early Breast Cancer

Prof. Sherene Loi of the Peter MacCallum Cancer Centre, University of Melbourne in Melbourne, Victoria, Australia and the BIG 1-98 study investigators reported on 8 July 2020 in the Annals of Oncology that in women with oestrogen receptor (ER)-positive/HER2-negative postmenopausal early breast cancer, PIK3CA mutations are associated with reduced risk of late distant recurrence, whereas amplifications on 8p11 and BRCA2 mutations are associated with increased risk of late distant recurrence. The characterisation of oncogenic driver alterations may aid in refining treatment choices for late disease recurrence in that setting and help in identifying potential drug targets for testing in future clinical trials.

The BIG 1-98 team wrote in the study background that in patients with postmenopausal, ER-positive/HER2-negative early breast cancer, the risk for distant recurrence extends beyond 5 years of adjuvant hormonal treatment.

In their study, the investigators aimed to identify genomic driver alterations associated with late distant recurrence. They used next generation sequencing to characterise driver alterations in primary tumours from a subset of 764 postmenopausal patients with ER-positive/HER2-negative breast cancer included in the BIG 1-98 randomised trial.

Late distant recurrence events were defined as at least 5 years from time of randomisation. The association of driver alterations with distant recurrence-free interval in early and late time periods was assessed using Cox regression models. Multivariable analyses were performed to adjust for clinicopathological factors. Weighted analysis methods were used in order to correct for over-sampling of distant recurrences.

In total, 538 of 764 samples (70%) were successfully sequenced including 88 early (63%) and 52 late (37%) distant recurrence events after a median follow-up of 8.1 years.

In univariable analysis for late distant recurrence, PIK3CA mutations (58.8%) were significantly associated with reduced risk (hazard ratio [HR] 0.40, 95% confidence interval [CI] 0.20-0.82, p = 0.012), whereas amplifications on chromosome 8p11 (10.9%) (HR 4.79, 95% CI 2.30-9.97, p < 0.001) and BRCA2 mutations (2.3%) (HR 5.39, 95% CI 1.51-19.29, p = 0.010) were significantly associated with an increased risk.

In multivariable analysis, only amplifications on 8p11 (p = 0.002) and BRCA2 mutations (p = 0.013) remained significant predictors.

The authors concluded that oncogenic driver characterisation may aid in refining prognostic estimates for late disease recurrence in women with ER-positive/HER2-negative postmenopausal early breast cancer.

Reference

Luen SJ, Asher R, Lee CK, et al. Identifying oncogenic drivers associated with increased risk of late distant recurrence in post-menopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study. Annals of Oncology; Published 8 July 2020. DOI: https://doi.org/10.1016/j.annonc.2020.06.024

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

2021 ASCO Annual Meeting Research Round Up: Advances in Treating Lung Cancer, Breast Cancer, and Sarcoma

In the annual Research Round Up series, Cancer.Net Associate Editors answer the question, “What was the most exciting or practice-changing research in your field...

Avapritinib Not Superior to Regorafenib in Terms of Median PFS in Third-Line or Later Treatment of Patients with Unresectable or Metastatic GIST

Findings from an open-label, randomised, multicentre phase III VOYAGER study indicate that avapritinib is not superior to regorafenib in terms of median progression-free survival...

Patients less likely to rate cancer care as ‘very good’ during pandemic

Almost a third of cancer patients have reported receiving worse care since COVID-19 began, according to a new survey commissioned by Cancer Research UK. Whilst...

How to Avoid Spreading Harmful Chemo Chemicals to Members of Your Household

Cancer is not contagious, and neither is chemotherapy. However, harmful chemotherapy drugs can sometimes still be present in the bodily fluids of a person...

The right combination for early detection

The upcoming Early Detection of Cancer Conference brings together experts from multiple disciplines to share ground breaking research and progress in the field. Here...

Can’t Sleep? Tips for Coping with Insomnia

Insomnia* is common for cancer patients**, as well as for the general population. We frequently hear from our patients and their caregivers that sleeping through the night...